Abstract 794P
Background
Cervical cancer is one of the leading causes of death for women in developing world and it is a preventable cancer, if precancerous lesions are identified early and treated promptly. India accounts for nearly one-third of the global cervical cancer deaths, with women facing a 1.6% cumulative risk of developing cervical cancer and 1.0% cumulative death risk from cervical cancer. This high incidence of deaths in India is mainly due to its detection in advanced stage. Reduction in mortality of the disease is possible only by effective screening methods which is reachable to peripheries of our country. Most commonly used screening tests india are VIA and Papsmear. The aim of the present study was to compare the efficacy of VIA with Papsmear cytology in screening for cancer cervix and evaluate their usefulness as tools for screening of premalignant and malignant lesions of the cervix so that VIA can be used in peripheral areas where cytology is not available. Detection of invasive carcinoma at the earliest stage.
Methods
It is Prospective Observational study Patients attending gynaecology outpatient department of CNMC, Kolkata, from the period between November 2018 and April 2020 were subjected to inclusion and exclusion criteria, eligible 100 patients were included in the study were subjected to VIA and Pap Smear along with colposcopy. Patient with positive VIA or Pap Biopsy was done.
Results
In our study group,37% of them were of age group 40- 49 years, high incidence of CIN was found among 37%in women with age group 40-49 years.58%women presented with white discharge per vagina. The sensitivity and specificity of VIA in our study are 86% and 74% respectively. Diagnostic accuracy is80%.PPV is 76%,NPV is 84% with colposcopy as reference standard. The sensitivity and specificity of papsmear in our study are 80% and 90% respectively.
Conclusions
VIA test has comparable results with pap smear in terms of sensitivity, specificity, PPV, NPV, diagnostic accuracy. Therefore it can be used as an alternative screening tool in screening pre malignant and malignant lesions of cervix in poor developing countries based on its efficacy, cost effectiveness and immediate results.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.